Table 1.

Reported randomized trials of targeted agents in renal cell cancer

Trial (ref)	Eligibility	N	Experimental arm	Control arm	Median PFS	Median OS
Motzer et al (24)	First-line, good and intermediate risk	750	Sunitinib	IFN α	11 vs5 mo∗	NA
Escudier et al (25)	Second-line, good and intermediate risk	905	Sorafenib	Placebo	24 vs12 wks∗	19.3 vs 15.9 mo∗
Escudier et al (26)	First-line, good risk	189 (II)	Sorafenib	IFN α	NA	NA
Yang et al(27)	Second-line, IL-2 refractory	116 (II)	Bevacizumab (high-dose)†	Placebo	4.8 vs 2.5 mo∗	NA
Bukowski et al (28)	First-line	104 (II)	Bevacizumab + erlotinib	Bevacizumab	9.9 vs 8.5 mo	NA
Hudes et al (29)	First-line, poor risk	626	Temsirolimus‡	IFN α	3.7 vs 1.9 mo∗	10.9 vs 7.3 mo∗

∗Statistically significant.

†Study contained a low-dose bevacizumab arm that did not extend PFS.

‡Study contained another arm of temsirolimus + IFN that did not extend survival.

Ref indicates reference; N, number of patients; PFS, progression-free survival; OS, overall survival; IFN, interferon; mo, months; NA, not available; II, randomized phase II trial; EGFR, epidermal growth factor receptor.